| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/19/2001 | CA2366599A1 Treatment of hepatitis c using hyperthermia |
| 07/18/2001 | EP1116516A1 Templating of solid particles by polymer multilayers |
| 07/18/2001 | EP1116488A2 Treatment of inflammatory Bowel disease |
| 07/18/2001 | EP1116487A2 Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery |
| 07/18/2001 | EP1116032A1 Gpr10 as a target for identifying weight modulating compounds |
| 07/18/2001 | EP1116028A1 Ndp |
| 07/18/2001 | EP1116027A1 Identifying agents that alter mitochondrial permeability transition pores |
| 07/18/2001 | EP1115887A1 Parallel selex |
| 07/18/2001 | EP1115882A1 Production and use of antimicrobial agents |
| 07/18/2001 | EP1115874A2 Alzheimer's disease secretase |
| 07/18/2001 | EP1115867A1 Human interleukin-b50. therapeutic uses |
| 07/18/2001 | EP1115865A2 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases |
| 07/18/2001 | EP1115864A2 Human chaperone proteins |
| 07/18/2001 | EP1115863A1 Ucp4 |
| 07/18/2001 | EP1115861A2 Alpha-synuclein super-mutants accelerate alpha-synuclein aggregation |
| 07/18/2001 | EP1115860A2 Membrane-associated organizational proteins |
| 07/18/2001 | EP1115743A1 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 07/18/2001 | EP1115733A1 Sequences characteristic of hypoxia-regulated gene transcription |
| 07/18/2001 | EP1115729A1 Phosphonic acid derivatives as inhibitors of ptp-1b |
| 07/18/2001 | EP1115703A1 Cyclic ester or amide derivatives |
| 07/18/2001 | EP1115701A1 Arylsulfonanilide ureas |
| 07/18/2001 | EP1115434A1 Adhesive protein foam for surgical and/or therapeutic uses |
| 07/18/2001 | EP1115423A1 Methods of downmodulating the immune response to therapeutic proteins |
| 07/18/2001 | EP1115419A2 Carbapenem antibacterial compositions and methods of treatment |
| 07/18/2001 | EP1115416A1 Use of substances with oxytocin activity in order to create cell regeneration |
| 07/18/2001 | EP1115412A1 Neuroimmunophilins for selective neuronal radioprotection |
| 07/18/2001 | EP1115406A2 Sustained release, and comfortable ophthalmic composition and method for ocular therapy |
| 07/18/2001 | EP1115405A1 Use of certain drugs for treating nerve root injury |
| 07/18/2001 | EP1115404A1 Use of prostanoid antagonists for the treatment of primary headache disorders |
| 07/18/2001 | EP1115402A1 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
| 07/18/2001 | EP1115397A1 Method of mitigating the adverse effects of interleukin-2 |
| 07/18/2001 | EP1115396A1 Pharmaceutically active compounds and methods of use thereof |
| 07/18/2001 | EP1115391A1 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
| 07/18/2001 | EP1115381A1 Proteinic drug delivery system using membrane mimetics |
| 07/18/2001 | EP1115379A2 Liquid pharmaceutical for oral delivery |
| 07/18/2001 | EP1115372A2 Fast dissolving orally consumable films |
| 07/18/2001 | EP1115286A1 Methods for treating or preventing viral infections and associated diseases |
| 07/18/2001 | EP0700288B1 Inhibition of hair growth |
| 07/18/2001 | CN1304453A Vaccine-induced hepatitis B viral strain and uses thereof |
| 07/18/2001 | CN1304322A Stabilization of compositions containing ACE inhibitors using magnesium oxide |
| 07/18/2001 | CN1304321A Composition for transdermal administration of non-steroidal anti-inflammatory drugs |
| 07/18/2001 | CN1304320A Drug composition containing PGD antagonists for curing inthing |
| 07/18/2001 | CN1304306A Method for inhibiting MRP1 |
| 07/18/2001 | CA2332169A1 Treatments for obesity and methods for identifiying compounds useful for treating obesity |
| 07/18/2001 | CA2296997A1 Treatment of congestive heart failure |
| 07/17/2001 | USRE37285 Polyoxypropylene/polyoxyethylene copolmers with improved biological activity |
| 07/17/2001 | US6262316 Administering a xanthophylles |
| 07/17/2001 | US6262246 DNA encoding mammalian neuropeptides FF (NPFF) receptors and uses thereof |
| 07/17/2001 | US6262233 Tissue factor pathway inhibitor-3 |
| 07/17/2001 | US6262127 Polymeric matrices and their uses in pharmaceutical compositions |
| 07/17/2001 | US6262118 Therapy of type 2 diabetes in a mammal by administering (-) 4-chlorophenyl-(3-trifluoromethylphenoxy)acetic acid derivative |
| 07/17/2001 | US6262116 Transcription therapy for cancers |
| 07/17/2001 | US6262111 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 07/17/2001 | US6262110 Farnesyl-protein transferase inhibitors |
| 07/17/2001 | US6262096 Aminothiazole inhibitors of cyclin dependent kinases |
| 07/17/2001 | US6262093 E.g., 2-(methoxycarbonylamino)benzimidazole. |
| 07/17/2001 | US6262081 Administering to the mammal a therapeutically effective amount of a combination of: (i) at least one neurotransmitter release enhancer, and (ii) at least one acetylcholinesterase inhibitor. |
| 07/17/2001 | US6262066 High affinity ligands for nociceptin receptor ORL-1 |
| 07/17/2001 | US6262032 Method of destroying hyperproliferative cells by combined p53 and taxoid treatment |
| 07/17/2001 | US6262021 Wounds of the skin, bone, mucus, tendons, muscles or connective tissue in mammals. |
| 07/17/2001 | US6261818 Nucleotide sequence of cardiac-related ankyrin-repeat protein kinase; antisense agents; probes; primers; vectors; host cells; antibodies; diagnosis and treatment of cardiovascular disorders |
| 07/17/2001 | US6261802 Ups (ugc) |
| 07/17/2001 | US6261801 Nucleic acids encoding tumor necrosis factor receptor 5 |
| 07/17/2001 | US6261791 Method for diagnosing cancer using specific PSCA antibodies |
| 07/17/2001 | US6261787 Bifunctional molecules for delivery of therapeutics |
| 07/17/2001 | US6261606 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 07/17/2001 | US6261572 In situ administering |
| 07/17/2001 | US6261544 Poly(hydroxy acid)/polymer conjugates for skin applications |
| 07/17/2001 | US6261279 Surgical irrigation solution and method for inhibition of pain and inflammation |
| 07/17/2001 | CA2065040C Arginine antagonists for inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
| 07/17/2001 | CA2034025C Fluid ophthalmic composition based on lipid microparticles containing at least one active principle |
| 07/12/2001 | WO2001050134A2 Methods of detection of amyloidogenic proteins |
| 07/12/2001 | WO2001049838A2 Cis-acting regulatory nucleic acid sequences in the parathyroid hormone 3'-untranslated region |
| 07/12/2001 | WO2001049715A2 Methods and compositions for inhibiting neoplastic cell growth |
| 07/12/2001 | WO2001049711A2 Nucleic acids encoding (poly)peptides having chips activity |
| 07/12/2001 | WO2001049680A1 Novel indole derivatives |
| 07/12/2001 | WO2001049323A1 Combination therapy for the treatment of inflammatory and respiratory diseases |
| 07/12/2001 | WO2001049322A1 Product comprising a heterotrimeric g protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension |
| 07/12/2001 | WO2001049315A1 Combination therapy for the treatment of inflammatory and respiratory diseases |
| 07/12/2001 | WO2001049314A2 Glp-2 formulations |
| 07/12/2001 | WO2001049311A1 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
| 07/12/2001 | WO2001049309A2 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue |
| 07/12/2001 | WO2001049307A1 Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses |
| 07/12/2001 | WO2001049303A1 Multivalent electron active compositions and methods of making and using same |
| 07/12/2001 | WO2001049302A1 Compositions and methods for facilitating skin growth and managing skin conditions |
| 07/12/2001 | WO2001049301A1 Methods of using electron active compounds for managing cancer |
| 07/12/2001 | WO2001049300A2 Combinations for the treatment of dna viral infections comprising a loop diuretic and lithium |
| 07/12/2001 | WO2001049296A1 Antimicrobial compositions and methods of use |
| 07/12/2001 | WO2001049294A1 Product for treating gynecomastia |
| 07/12/2001 | WO2001049290A1 Methods and reagents for facilitating transcription |
| 07/12/2001 | WO2001049289A1 Pharmaceutical and veterinary uses of endothelin antagonists |
| 07/12/2001 | WO2001049287A1 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| 07/12/2001 | WO2001049286A1 Method and formulation for treating resistance to antihypertensives and related conditions |
| 07/12/2001 | WO2001049285A1 Flavonoid drug and dosage form, its production and use |
| 07/12/2001 | WO2001049284A1 Composition for stabilizing and potentiating the action of anti-angiogenic substances by polyunsaturated fatty acids |
| 07/12/2001 | WO2001049278A2 Compounds and compositions for use in inhibiting endoparasitic fatty acid biosynthesis |
| 07/12/2001 | WO2001049263A1 Inhalation particles |
| 07/12/2001 | WO2001049250A2 Treatment of acne using lipoic acid |
| 07/12/2001 | WO2001049242A2 Combinations for the treatment of dna viral infections comprising a loop diuretic cardiac glycoside |
| 07/12/2001 | WO2001008677A8 Methods of inhibiting osteoclast activity |